GlassScriptPhysician profile
Naing Lin Htike
NPI 1891020871
$2,669.37
in general payments reported to CMS, 2019-2025
22 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.88 · 2021: $114 · 2022: $95.84 · 2023: $322 · 2024: $696 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.81 |
| Education | $104.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $520.76 | 2023-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $416.10 | 2024-2025 | |
| Travere Therapeutics, INC. | $296.48 | 2023-2025 | Filspari |
| Vifor Pharma, INC. | $218.75 | 2023-2025 | Veltassa, Korsuva |
| Lilly USA, LLC | $165.02 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $142.05 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $138.37 | 2019-2025 | Farxiga |
| Daxor Corporation | $110.71 | 2023 | Bva-100 |
| Amgen INC. | $107.69 | 2024 | Tavneos |
| Veloxis Pharmaceuticals, INC. | $95.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $89.42 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $66.52 | 2025 | Acthar, Terlivaz |
| Opko Pharmaceuticals, LLC | $62.43 | 2025 | Rayaldee |
| Novo Nordisk INC | $48.15 | 2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.08 | 2025 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.08 | 2021-2025 | Arexvy, Shingrix |
| Akebia Therapeutics INC | $26.70 | 2024 | Vafseo |
| Cormedix INC. | $23.42 | 2024 | Defencath |
| Apellis Pharmaceuticals, INC. | $20.89 | 2025 | Empaveli |
| Calliditas Therapeutics US INC. | $20.10 | 2025 | Tarpeyo |
| Nxstage Medical, INC. | $19.94 | 2025 | Liberty Select Cycler, Nxstage System One |
| Fresenius USA Marketing, INC. | $18.87 | 2024 | Velphoro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naing Htike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.